31st May 2023 12:09
MGC Pharmaceuticals Ltd - London-based pharmaceutical company specialising in plant-inspired medicines - Says its investigational medicinal product, CannEpil, has been successfully delivered to its first UK patients through I Am Billy Foundation. Says CannEpil also has been delivered to its first patient in the UK through a named patient request programme.
CannEpil is a high-cannabidiol, low-tetrahydrocannabinol oral mucosal solution used to treat patients suffering from epilepsy. It was made available in 2019 for distribution and prescription in Ireland under full governmental health insurance coverage. Last month, MGC announced CannEpil would become available in the UK through a named patient request, prescribed by doctors.
I Am Billy is a British charity focused on making "life-changing medicine" more accessible through grassroots campaigning.
Chief Executive Officer Roby Zomer says: "We know there is a huge unmet need for epilepsy treatment, and we are pleased to be partnering with I Am Billy Foundation on this important work. With our combined knowledge, expertise, and capabilities, our aim is to facilitate patient access to the highest-quality cannabis-based medicinal products for patients with this huge unmet need."
Current stock price: 0.38 pence, down 1.3%
12-month change: down 65%
By Sabrina Penty, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
MXC.L